Vitamin D Analogs for Treating Bone Cancers and Diseases

INVENTORS • Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Izabela Sibilska, Rafal Sicinski

WARF: P100358US03
View U.S. Patent No. 8,993,547 in PDF format.

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing vitamin D analogs with high calcemic activity that may be useful in as anti-cancer agents, especially in the treatment and prevention of osteosarcomas.

OVERVIEW

The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D₃, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for new compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.

THE INVENTION

UW–Madison researchers have developed vitamin D analogs, (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D₃ and (20R)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D₃. These compounds exhibit promising anti-cancer activities: high receptor binding, and the arrest and induced-differentiation of proliferating cells. High calcemic mobilization suggests particular effectiveness in the treatment of bone diseases.

APPLICATIONS

• Therapy for bone diseases, osteoporosis and osteosarcoma
• Prevention and treatment of leukemia, skin cancer, breast cancer, colon cancer and prostate cancer

KEY BENEFITS

• High bone calcium mobilization
• Lower intestinal calcium transport activity
• Can be administered in many forms

ADDITIONAL INFORMATION

Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
Pharmaceuticals & Vitamin D - Oncology & hematology
Pharmaceuticals & Vitamin D - Immunity & auto-immune

CONTACT INFORMATION

For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.